Table 2 Incidence rates of cancer in LTRA users and non-users.

From: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients

 

All patients

LTRA non-users

IR

LTRA users

IRR [95% CI]

aIRR [95% CI]

N

Cancer

PY

IR

N

Cancer

PY

N

Cancer

PY

IR

Whole study population Stratified analyses

25110

1197

100593.2

11.9

20925

1104

84593.3

13.1

4185

93

15999.9

5.8

0.45 [0.39–0.51]***

0.41 [0.36–0.47]***

Sex

 Female

14934

625

61015.7

10.2

12445

585

51404.0

11.4

2489

40

9611.7

4.2

0.37 [0.30–0.44]***

0.34 [0.28–0.41]***

 Male

10176

572

39577.5

14.5

8480

519

33189.3

15.6

1696

53

6388.2

8.3

0.53 [0.44–0.64]***

0.49 [0.41–0.58]***

Age

 Age ≤40

9559

109

43348.8

2.5

7936

104

36702.5

2.8

1623

5

6646.3

0.8

0.27 [0.19–0.36]***

0.27 [0.20–0.37]***

 40< Age ≤65

11061

620

43523.3

14.2

9247

570

36702.9

15.5

1814

50

6820.4

7.3

0.47 [0.39–0.57]***

0.45 [0.37–0.55]***

 Age >65

4490

468

13721.1

34.1

3742

430

11187.9

38.4

748

38

2533.2

15.0

0.39 [0.30–0.51]***

0.38 [0.29–0.50]***

Residency

 Northern Taiwan

13836

589

56174.4

10.5

11191

530

46127.2

11.5

2645

59

10047.2

5.9

0.51 [0.43–0.60]***

0.43 [0.37–0.50]***

 Other areas

11274

608

44418.8

13.7

9734

574

38466.1

14.9

1540

34

5952.7

5.7

0.38 [0.30–0.48]***

0.38 [0.30–0.47]***

Monthly income

 ≤NT$24000

12290

759

47025.8

16.1

10412

708

39915.9

17.7

1878

51

7109.9

7.2

0.40 [0.33–0.49]***

0.36 [0.30–0.44]***

 >NT$24000

12820

438

53567.4

8.2

10513

396

44677.4

8.9

2307

42

8890.0

4.7

0.53 [0.45–0.64]***

0.48 [0.41–0.57]***

Marriage status

 Married

16049

921

64873.1

14.2

13409

845

54554.7

15.5

2640

76

10318.4

7.4

0.48 [0.41–0.56]***

0.44 [0.38–0.51]***

 Not married

9061

276

35720.1

7.7

7516

259

30038.6

8.6

1545

17

5681.5

3.0

0.35 [0.27–0.45]***

0.31 [0.24–0.39]***

Education level

 Elementary school or lower

9616

731

34513.9

21.2

8131

680

29182.4

23.3

1485

51

5331.6

9.6

0.41 [0.33–0.51]***

0.39 [0.32–0.48]***

 High school

11136

348

47369.8

7.3

9310

319

40247.0

7.9

1826

29

7122.8

4.1

0.51 [0.42–0.63]***

0.43 [0.35–0.52]***

 College or higher

4358

118

18709.5

6.3

3484

105

15163.9

6.9

874

13

3545.6

3.7

0.53 [0.39–0.71]***

0.42 [0.32–0.55]***

With comorbidity

 No (mCCI score = 0)

16500

685

71023.6

9.6

13750

636

59945.8

10.6

2750

49

11077.8

4.4

0.42 [0.35–0.50]***

0.38 [0.32–0.44]***

 Yes (mCCI score ≥ 1)

8610

512

29569.6

17.3

7175

468

24647.5

19.0

1435

44

4922.1

8.9

0.47 [0.38–0.58]***

0.45 [0.37–0.55]***

  1. The subjects were followed from a year after the index date to either development of cancer, death or the end of 2011, whichever came first.
  2. The incidence rate (IR) is expressed as incident cancer per 1000 patient-years. The IRs of cancer in LTRA users and non-users were compared by estimating the incidence rate ratio (IRR) using Poisson regression and adjusted IRR (aIRR) using multivariable Poisson regression after adjusting for age, residency, income level, marriage status, education level and the presence of various comorbidities (except for the variable used for stratification).
  3. *P < 0.05; **P < 0.01; ***P < 0.0001.
  4. Abbreviation: N = number of patients; Cancer = number of patients with incident cancer; PY = total patient-years of follow-up; CI = confidence interval.
Back to article page